The growth trajectory for Indian pharmaceutical industry is likely to be moderate on back of slowing growth from US given the relatively moderate proportion of large size drugs going off patent, increased competition leading to price erosion in low–to--mid-teens, generic adoption reaching saturation ...
Read more: Several odds likely to curtail Indian pharma growth to single digit: ICRA